Subscribe
Magazine
Videos
Advertise
About Us
Smart Water Summit
Wastewater Summit
Drinking Water
Smart Water
Asset Management
Water Utility Management
Water Reuse
Global Thought Leaders
Podcast
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
WaterWorld Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Skye Bioscience Inc
(OP:
SKYE
)
N/A
UNCHANGED
Last Price
Updated: 3:57 PM EDT, Apr 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Skye Bioscience Inc
< Previous
1
2
Next >
Skye Bioscience Announces $40 Million Private Placement Equity Financing
March 11, 2024
San Diego, California--(Newsfile Corp. - March 11, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) (the Company), a clinical stage biotechnology...
Via
Newsfile
Skye Bioscience to Present at Oppenheimer Investor Conference
February 07, 2024
San Diego, California--(Newsfile Corp. - February 7, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a clinical-stage biotechnology company focused...
Via
Newsfile
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing
January 29, 2024
San Diego, California--(Newsfile Corp. - January 29, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("the Company"), a clinical stage biotechnology...
Via
Newsfile
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
January 09, 2024
San Francisco, California--(Newsfile Corp. - January 9, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa
December 05, 2023
San Diego, California and Johannesburg, South Africa--(Newsfile Corp. - December 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a...
Via
Newsfile
Topics
Cannabis
Intellectual Property
Exposures
Cannabis
Intellectual Property
Skye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit
November 21, 2023
San Diego, California--(Newsfile Corp. - November 21, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs...
Via
Newsfile
Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma
October 25, 2023
• SBI-100 OE is well tolerated, with low rate of hyperaemia...
Via
Newsfile
CORRECTION: Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"
October 20, 2023
This document replaces and updates the previous version with the current OTCQB ticker for Skye Bioscience, Inc.San Diego, California--(Newsfile Corp....
Via
Newsfile
Skye Bioscience to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
San Diego, California--(Newsfile Corp. - September 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing proprietary...
Via
Newsfile
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
August 21, 2023
New capital funds anticipated Phase 2a glaucoma clinical trial Nimacimab is a first-in-class peripherally-restricted negative allosteric modulator antibody inhibitor of...
Via
Newsfile
Skye Bioscience to Present at H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
August 14, 2023
San Diego, California--(Newsfile Corp. - August 14, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing a...
Via
Newsfile
Skye Bioscience Receives Positive Safety Review for Final Cohort of Fully-Enrolled Phase 1 Study of SBI-100 Ophthalmic Emulsion
July 13, 2023
San Diego, California--(Newsfile Corp. - July 13, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Skye Bioscience Completes Production and Filling of Investigational Drug Material in Preparation for Phase 2a Glaucoma Clinical Trial
July 06, 2023
San Diego, California--(Newsfile Corp. - July 6, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Skye Bioscience Completes Enrollment of Phase 1 Clinical Trial of Novel CB1R Agonist, SBI-100 Ophthalmic Emulsion
June 12, 2023
San Diego, California--(Newsfile Corp. - June 12, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Skye Bioscience to Present at LD Micro Invitational XIII
June 05, 2023
San Diego, California--(Newsfile Corp. - June 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Skye Bioscience Receives Positive Safety Review of Fifth Cohort of Phase 1 Study of SBI-100 Ophthalmic Emulsion
June 02, 2023
San Diego, California--(Newsfile Corp. - June 2, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Topics
Derivatives
Exposures
Derivatives
Skye Bioscience Begins Dosing Fifth of Six Cohorts in Phase 1 Clinical Trial of Novel CB1R Agonist
May 17, 2023
San Diego, California--(Newsfile Corp. - May 17, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Skye Bioscience Receives Positive Safety Review in First Multiple-Administration Cohort of Phase 1 Study of SBI-100 Ophthalmic Emulsion
May 15, 2023
San Diego, California--(Newsfile Corp. - May 15, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Skye Bioscience Begins Dosing Phase 1 Fourth Cohort in Clinical Trial of Novel CB1R Agonist
April 27, 2023
Skye progresses to multiple ascending dose arm of SBI-100 Ophthalmic Emulsion trial after completing single ascending dose armP1 dosing of...
Via
Newsfile
Skye Bioscience Receives Positive Safety Review of Third Cohort in Phase 1 Study of SBI-100 Ophthalmic Emulsion
April 04, 2023
San Diego, California--(Newsfile Corp. - April 4, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Topics
Derivatives
Exposures
Derivatives
Skye Bioscience's Novel Cannabinoid Derivative Reduces Pain in Animal Model; Results Published in Scientific Journal
April 03, 2023
San Diego, California--(Newsfile Corp. - April 3, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Topics
Cannabis
Exposures
Cannabis
Skye Bioscience Receives Human Research Ethics Committee Approval to Start Multiple Ascending Dose Arm of Phase 1 Study of SBI-100 Ophthalmic Emulsion
March 15, 2023
San Diego, California--(Newsfile Corp. - March 15, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Skye Bioscience Doses Third Cohort of Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion
March 07, 2023
San Diego, California--(Newsfile Corp. - March 7, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Topics
Derivatives
Exposures
Derivatives
Skye Bioscience Receives Positive Safety Review of SBI-100 Ophthalmic Emulsion After Second Cohort of Phase 1 Study
February 23, 2023
San Diego, California--(Newsfile Corp. - February 23, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Skye Bioscience Appoints Deborah Charych, PhD to Board of Directors
February 16, 2023
San Diego, California--(Newsfile Corp. - February 16, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Skye Bioscience Closes Sale of Subsidiary, Verdélite Sciences, to C3 Souvenir Holding, with USD$5.60M Closing Payment
February 15, 2023
San Diego, California--(Newsfile Corp. - February 15, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Topics
Cannabis
Exposures
Cannabis
Skye Bioscience Doses Second Cohort of Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion
February 13, 2023
San Diego, California--(Newsfile Corp. - February 13, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Skye Bioscience Retains Lexitas Pharma Services as CRO for Phase 2 Trial of SBI-100 Ophthalmic Emulsion
February 02, 2023
San Francisco, California--(Newsfile Corp. - February 2, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Topics
Derivatives
Exposures
Derivatives
Skye Bioscience Achieves Positive Safety Review of SBI-100 Ophthalmic Emulsion After Phase 1 First Cohort
January 31, 2023
San Diego, California--(Newsfile Corp. - January 31, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Skye Bioscience Obtains Central IRB Approval for Phase 2 Clinical Trial with SBI-100 Ophthalmic Emulsion
January 27, 2023
San Diego, California--(Newsfile Corp. - January 27, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Exposures
Product Safety
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.